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Abstract: 
 
      We have used a translational convergent functional genomics (CFG) approach to identify 
and prioritize genes involved in schizophrenia, by gene-level integration of genome-wide 
association study (GWAS) data with other genetic and gene expression studies in humans and 
animal models. Using this polyevidence scoring and pathway analyses, we identify top genes 
(DISC1, TCF4, MBP, MOBP, NCAM1, NRCAM, NDUFV2, RAB18, as well as ADCYAP1, 
BDNF, CNR1, COMT, DRD2, DTNBP1, GAD1, GRIA1, GRN2B, HTR2A, NRG1,  RELN, SNAP-
25, TNIK), brain development, myelination, cell adhesion, glutamate receptor signaling, G-
protein coupled receptor signaling and cAMP- mediated signaling as key to pathophysiology 
and as targets for therapeutic intervention. Overall, the data is consistent with a model of 
disrupted connectivity in schizophrenia, resulting from the effects of neurodevelopmental 
environmental stress on a background of genetic vulnerability. In addition, we show how the top 
candidate genes identified by CFG can be used to generate a genetic  risk prediction score 
(GRPS) to aid schizophrenia diagnostics, with predictive ability in independent cohorts. The 
GRPS also differentiates classic age of onset  schizophrenia from early onset and late-onset 
disease. We also show, in three independent cohorts,  two European-American (EA) and one 
African-American (AA), increasing overlap, reproducibility and consistency of findings from 
SNPs to genes, then genes  prioritized by CFG, and ultimately at the level of biological 
pathways and mechanisms. Lastly, we compared our top candidate genes for schizophrenia 
from this analysis with top candidate genes for bipolar disorder and anxiety disorders from 
previous CFG analyses conducted by us, as well as findings from the fields of autism and 
Alzheimer. Overall, our work maps the genomic and biological landscape for schizophrenia, 
providing leads towards a better understanding of illness, diagnostics, and therapeutics. It also 
reveals the significant genetic overlap with other major psychiatric disorder domains, suggesting 
the need for improved nosology. 
